Grifols, S.A. (NASDAQ:GRFS) Shares Sold by Fmr LLC

Fmr LLC decreased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 22.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,646 shares of the biotechnology company’s stock after selling 7,074 shares during the quarter. Fmr LLC’s holdings in Grifols were worth $219,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Brandes Investment Partners LP increased its position in shares of Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after acquiring an additional 1,481,924 shares during the period. Black Creek Investment Management Inc. grew its stake in Grifols by 7.7% during the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after purchasing an additional 881,155 shares during the last quarter. Armistice Capital LLC increased its holdings in shares of Grifols by 18.7% in the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares during the period. Whitebox Advisors LLC raised its stake in shares of Grifols by 45.6% in the second quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company’s stock worth $17,039,000 after purchasing an additional 846,940 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Grifols by 4.7% during the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock worth $13,931,000 after purchasing an additional 100,131 shares during the period.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 2.7 %

Shares of Grifols stock opened at $7.51 on Friday. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The stock has a market cap of $5.16 billion, a PE ratio of 7.74 and a beta of 0.43. The firm has a fifty day moving average price of $8.35 and a 200 day moving average price of $8.10.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.